Andreas Kogelnik: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
VisualWikitext
m (Text replacement - " \| ?last(.*)\=(.*)( *)\| ?first(.*)\=(.*)( *)\| ?author" to " |last$1=$2 |first$3$4 |author")
m (Undo revision 110726 by Notjusttired (talk))
Line 60: Line 60:
==References==
==References==
<references>
<references>
<ref name="Montoya, 2013">{{Citation |last1  = Montoya |first        1  |authorlink1 = Jose Montoya |last2  = Kogelnik |first        2  |authorlink2 = Andreas Kogelnik |last3  = Bhangoo |first        3  |authorlink3 = |last4  = Lunn |first            4  |authorlink4 = |last5  = Flamand |first        5  |authorlink5 = |last6  = Merrihew |first        6  |authorlink6 = |last7  = Watt |first            7  |authorlink7 = |last8  = Kubo |first            8  |authorlink8 = |last9  = Paik |first            9  |authorlink9 = |last10  = Desai |first          10  |authorlink10 =
<ref name="Montoya, 2013">{{Citation
| last1  = Montoya         | first1 = JG              | authorlink1 = Jose Montoya
| last2  = Kogelnik       | first2 = AM              | authorlink2 = Andreas Kogelnik
| last3  = Bhangoo         | first3 = M              | authorlink3 =  
| last4  = Lunn           | first4 = MR              | authorlink4 =  
| last5  = Flamand         | first5 = L              | authorlink5 =  
| last6  = Merrihew       | first6 = LE              | authorlink6 =  
| last7  = Watt           | first7 = T              | authorlink7 =  
| last8  = Kubo           | first8 = JT              | authorlink8 =  
| last9  = Paik           | first9 = J              | authorlink9 =
| last10  = Desai           | first10 = M              | authorlink10 =
| title  = Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
| title  = Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
| journal = Journal of Medical Virology    | volume = 85  | issue = 12  | page = 2101-9
| journal = Journal of Medical Virology    | volume = 85  | issue = 12  | page = 2101-9
Line 68: Line 78:
}}
}}
</ref>
</ref>
<ref name="Unger, 2017">{{Citation |last1  = Unger |first        1  |authorlink1 = Elizabeth Unger |last2  = Lin |first          2  |authorlink2 = Jin-Mann Sally Lin |last3  = Tian |first        3  |authorlink3 = |last4  = Natelson |first    4  |authorlink4 = Benjamin Natelson |last5  = Lange |first        5  |authorlink5 = Gudrun Lange |last6  = Vu |first           6  |authorlink6 = |last7  = Blate |first       7  |authorlink7 = |last8  = Klimas |first      8  |authorlink8 = Nancy Klimas   |last9  = Balbin |first      9  |authorlink9 = Elizabeth Balbin |last10  = Bateman |first      10  |authorlink10 = Lucinda Bateman |last11  = Allen |first        11  |authorlink11 =   |last12  = Lapp |first        12  |authorlink12 = Charles Lapp |last13  = Springs |first      13  |authorlink13 =   |last14  = Kogelnik |first     14  |authorlink14 = Andreas Kogelnik |last15  = Phan |first        15  |authorlink15 =   |last16  = Danver |first      16  |authorlink16 =   |last17  = Podell |first      17  |authorlink17 = Richard Podell  
<ref name="Unger, 2017">{{Citation
| last18  = Fitzpatrick  | first18 = Trisha        | authorlink18 =   |last19  = Peterson |first    19  |authorlink19 = Daniel Peterson  
| last1  = Unger       | first1 = Elizabeth R.    | authorlink1 = Elizabeth Unger
| last2  = Lin         | first2 = Jin-Mann S.    | authorlink2 = Jin-Mann Sally Lin
| last3  = Tian         | first3 = Hao            | authorlink3 =  
| last4  = Natelson     | first4 = Benjamin H      | authorlink4 = Benjamin Natelson  
| last5  = Lange       | first5 = Gudrun          | authorlink5 = Gudrun Lange
| last6  = Vu           | first6 = Diana           | authorlink6 =  
| last7  = Blate       | first7 = Michelle       | authorlink7 =  
| last8  = Klimas       | first8 = Nancy G.        | authorlink8 = Nancy Klimas
| last9  = Balbin       | first9 = Elizabeth G.    | authorlink9 = Elizabeth Balbin  
| last10  = Bateman     | first10 = Lucinda        | authorlink10 = Lucinda Bateman  
| last11  = Allen       | first11 = Ali            | authorlink11 =
| last12  = Lapp         | first12 = Charles W.    | authorlink12 = Charles Lapp  
| last13  = Springs     | first13 = Wendy          | authorlink13 =
| last14  = Kogelnik     | first14 = Andreas M.     | authorlink14 = Andreas Kogelnik  
| last15  = Phan         | first15 = Catrina C.    | authorlink15 =
| last16  = Danver       | first16 = Joan          | authorlink16 =
| last17  = Podell       | first17 = Richard N.    | authorlink17 = Richard Podell  
| last18  = Fitzpatrick  | first18 = Trisha        | authorlink18 =
| last19  = Peterson     | first19 = Daniel L.      | authorlink19 = Daniel Peterson  
| last20  = Gottschalk  | first20 =  C. Gunnar    | authorlink20 = Gunnar Gottschalk
| last20  = Gottschalk  | first20 =  C. Gunnar    | authorlink20 = Gunnar Gottschalk
| last21  = Rajeevan    | first21 = Mangalathu S.  | authorlink21 = Mangalathu Rajeevan
| last21  = Rajeevan    | first21 = Mangalathu S.  | authorlink21 = Mangalathu Rajeevan

Revision as of 22:37, May 11, 2022

Source: www.openmedicinefoundation.org

Andreas ("Andy") M. Kogelnik, MD, PhD, is an internal medicine and infectious diseases specialist and the director of the Open Medicine Institute, Mountain View, California, US.[1] His interests are in bioinformatics and genomic medicine and is committed to the study and treatment of ME/CFS and other chronic illnesses.[1]

Education[edit | edit source]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Kogelnik is a member of the Immune Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project, sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[2]

Research publications on ME/CFS[edit | edit source]

Articles[edit | edit source]

Talks and interviews[edit | edit source]

The Open Medicine Institute, Part 1,
The Open Medicine Institute, Part 2,
The Open Medicine Institute, Part 3
Interview with Dr. Andreas Kogelnik, Part 1
Interview with Dr. Andreas Kogelnik, Part 2

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "The Clinic". Open Medicine Institute. Retrieved April 17, 2019.
  2. ↑ "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
  3. ↑ Kogelnik, AM; Loomis, K; Hoegh-Petersen, M; Rosso, F; Hischier, C; Montoya, JG. "Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue". Journal of Clinical Virology. 37: Suppl 1:S33-8. doi:10.1016/S1386-6532(06)70009-9. PMID 17276366.
  4. ↑ Knox, K.; Carrigan, D.; Simmons, G.; Teque, F.; Zhou, Y.; Hackett, J.; Qiu, X.; Luk, K.-C.; Schochetman, G.; Kogelnik, AM (July 1, 2011). "No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected". Science. 333 (6038): 94–97. doi:10.1126/science.1204963. ISSN 0036-8075.
  5. ↑ Montoya, JG; Kogelnik, AM; Bhangoo, M; Lunn, MR; Flamand, L; Merrihew, LE; Watt, T; Kubo, JT; Paik, J; Desai, M (2013), "Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.", Journal of Medical Virology, 85 (12): 2101-9, doi:10.1002/jmv.23713, PMID 23959519
  6. ↑ Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  7. ↑ "Invest in ME Research - UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
  8. ↑ "Invest in ME Research - UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
  9. ↑ "Invest in ME Research - UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.

chronic illness any long-term illness, regardless of the severity. Chronic illnesses are typically incurable, requiring long-term management.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Retrieved from "https://me-pedia.org/w/index.php?title=Andreas_Kogelnik&oldid=111296"